SMAD3 regulates gonadal tumorigenesis

Molecular Endocrinology

Volumn 21, Issue 10, 2007, Pages 2472-2486

  Li, Qinglei ^a   Graff, Jonathan M ^b   O'Connor, Anne E ^c   Loveland, Kate L ^c   Matzuk, Martin M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; INHIBIN A; SMAD3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACHEXIA; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GONADAL CELL TUMOR; MALE; MOUSE; NONHUMAN; OVARY TUMOR; PATHOGENESIS; PRIORITY JOURNAL; TESTIS TUMOR; WASTING SYNDROME; WEIGHT REDUCTION;

ACTIVINS; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FOLLICLE STIMULATING HORMONE; INHIBINS; MALE; MICE; MICE, KNOCKOUT; OVARIAN NEOPLASMS; RNA, MESSENGER; SMAD3 PROTEIN; TESTICULAR NEOPLASMS; WASTING SYNDROME; WEIGHT LOSS;

MUS;

EID: 34548386862     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2007-0147     Document Type: Article

References (67)

1. Chang H, Brown CW, Matzuk MM 2002 Genetic analysis of the mammalian transforming growth factor-β super-family. Endocr Rev 23:787-823
2. Massague J 1998 TGF-β signal transduction. Annu Rev Biochem 67:753-791
3. Massague J 2000 How cells read TGF-β signals. Nat Rev Mol Cell Biol 1:169-178
4. Risbridger GP, Schmitt JF, Robertson DM 2001 Activins and inhibins in endocrine and other tumors. Endocr Rev 22:836-858
5. Xu J, McKeehan K, Matsuzaki K, McKeehan WL 1995 Inhibin antagonizes inhibition of liver cell growth by activin by a dominant-negative mechanism. J Biol Chem 270:6308-6313
6. Bilezikjian LM, Blount AL, Donaldson CJ, Vale WW 2006 Pituitary actions of ligands of the TGF-β family: activins and inhibins. Reproduction 132:207-215
7. Findlay JK, Drummond AE, Dyson M, Baillie AJ, Robertson DM, Ethier JF 2001 Production and actions of inhibin and activin during folliculogenesis in the rat. Mol Cell Endocrinol 180:139-144
8. Yan W, Burns KH, Matzuk MM 2003 Genetic engineering to study testicular tumorigenesis. APMIS 111:174-181; discussion 182-183
9. Pangas SA, Woodruff TK 2000 Activin signal transduction pathways. Trends Endocrinol Metab 11:309-314
10. Brown CW, Li L, Houston-Hawkins DE, Matzuk MM 2003 Activins are critical modulators of growth and survival. Mol Endocrinol 17:2404-2417
11. Bristol-Gould SK, Kreeger PK, Selkirk CG, Kilen SM, Cook RW, Kipp JL, Shea LD, Mayo KE, Woodruff TK 2006 Postnatal regulation of germ cells by activin: the establishment of the initial follicle pool. Dev Biol 298:132-148
12. Phillips DJ, Woodruff TK 2004 Inhibin: actions and signalling. Growth Factors 22:13-18
13. Loveland KL, Robertson DM 2005 The TGFb superfamily in Sertoli cell biology. In: Griswold M, Skinner M, eds. Sertoli cell biology. New York: Elsevier Science; 227-247
14. Matzuk MM, Finegold MJ, Su JG, Hsueh AJ, Bradley A 1992 α-Inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 360:313-319
15. Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H, Bradley A 1994 Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci USA 91:8817-8821
16. Matzuk MM, Kumar TR, Shou W, Coerver KA, Lau AL, Behringer RR, Finegold MJ 1996 Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development. Recent Prog Horm Res 51:123-154; discussion 155-157
17. Coerver KA, Woodruff TK, Finegold MJ, Mather J, Bradley A, Matzuk MM 1996 Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice. Mol Endocrinol 10:534-543
18. Derynck R, Zhang YE 2003 Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425:577-584
19. Massague J 1992 Receptors for the TGF-β family. Cell 69:1067-1070
20. Mathews LS, Vale WW 1991 Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell 65:973-982
21. Attisano L, Carcamo J, Ventura F, Weis FM, Massague J, Wrana JL 1993 Identification of human activin and TGF β type I receptors that form heteromeric kinase complexes with type II receptors. Cell 75:671-680
22. Mathews LS 1994 Activin receptors and cellular signaling by the receptor serine kinase family. Endocr Rev 15:310-325
23. Matzuk MM, Kumar TR, Vassalli A, Bickenbach JR, Roop DR, Jaenisch R, Bradley A 1995 Functional analysis of activins during mammalian development. Nature 374:354-356
24. Mehra A, Wrana JL 2002 TGF-β and the Smad signal transduction pathway. Biochem Cell Biol 80:605-622
25. Moustakas A, Souchelnytskyi S, Heldin CH 2001 Smad regulation in TGF-β signal transduction. J Cell Sci 114:4359-4369
26. Massague J, Blain SW, Lo RS 2000 TGFβ signaling in growth control, cancer, and heritable disorders. Cell 103:295-309
27. ten Dijke P, Hill CS 2004 New insights into TGF-β-Smad signalling. Trends Biochem Sci 29:265-273
28. Suszko MI, Lo DJ, Suh H, Camper SA, Woodruff TK 2003 Regulation of the rat follicle-stimulating hormone β-subunit promoter by activin. Mol Endocrinol 17:318-332
29. Bernard DJ 2004 Both SMAD2 and SMAD3 mediate activin-stimulated expression of the follicle-stimulating hormone β subunit in mouse gonadotrope cells. Mol Endocrinol 18:606-623
30. Hamamoto T, Beppu H, Okada H, Kawabata M, Kitamura T, Miyazono K, Kato M 2002 Compound disruption of smad2 accelerates malignant progression of intestinal tumors in apc knockout mice. Cancer Res 62:5955-5961
31. Heyer J, Escalante-Alcalde D, Lia M, Boettinger E, Edelmann W, Stewart CL, Kucherlapati R 1999 Postgastrulation Smad2-deficient embryos show defects in embryo turning and anterior morphogenesis. Proc Natl Acad Sci USA 96:12595-12600
32. Nomura M, Li E 1998 Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature 393:786-790
33. Waldrip WR, Bikoff EK, Hoodless PA, Wrana JL, Robertson EJ 1998 Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo. Cell 92:797-808
34. Weinstein M, Yang X, Li C, Xu X, Gotay J, Deng CX 1998 Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor smad2. Proc Natl Acad Sci USA 95:9378-9383
35. Zhu Y, Richardson JA, Parada LF, Graff JM 1998 Smad3 mutant mice develop metastatic colorectal cancer. Cell 94:703-714
36. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, Roberts AB, Deng C 1999 Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. EMBO J 18:1280-1291
37. Kumar TR, Palapattu G, Wang P, Woodruff TK, Boime I, Byrne MC, Matzuk MM 1999 Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis. Mol Endocrinol 13:851-865
38. Burns KH, Agno JE, Chen L, Haupt B, Ogbonna SC, Korach KS, Matzuk MM 2003 Sexually dimorphic roles of steroid hormone receptor signaling in gonadal tumorigenesis. Mol Endocrinol 17:2039-2052
39. Shikone T, Matzuk MM, Perlas E, Finegold MJ, Lewis KA, Vale W, Bradley A, Hsueh AJ 1994 Characterization of gonadal sex cord-stromal tumor cell lines from inhibin-α and p53-deficient mice: the role of activin as an autocrine growth factor. Mol Endocrinol 8:983-995
40. Xu J, Oakley J, McGee EA 2002 Stage-specific expression of Smad2 and Smad3 during folliculogenesis. Biol Reprod 66:1571-1578
41. Gueripel X, Benahmed M, Gougeon A 2004 Sequential gonadotropin treatment of immature mice leads to amplification of transforming growth factor β action, via upregulation of receptor-type 1, Smad 2 and 4, and downregulation of Smad 6. Biol Reprod 70:640-648
42. Tomic D, Miller KP, Kenny HA, Woodruff TK, Hoyer P, Flaws JA 2004 Ovarian follicle development requires Smad3. Mol Endocrinol 18:2224-2240
43. Xu J, Beyer AR, Walker WH, McGee EA 2003 Developmental and stage-specific expression of Smad2 and Smad3 in rat testis. J Androl 24:192-200
44. Wang RA, Zhao GQ 1999 Transforming growth factor β signal transducer Smad2 is expressed in mouse meiotic germ cells, Sertoli cells, and Leydig cells during spermatogenesis. Biol Reprod 61:999-1004
45. Trudeau VL, Matzuk MM, Hache RJ, Renaud LP 1994 Overexpression of activin-β A subunit mRNA is associated with decreased activin type II receptor mRNA levels in the testes of α-inhibin deficient mice. Biochem Biophys Res Commun 203:105-112
46. Smith JC, Price BM, Van Nimmen K, Huylebroeck D 1990 Identification of a potent Xenopus mesoderm-inducing factor as a homologue of activin A. Nature 345:729-731
47. Wittbrodt J, Rosa FM 1994 Disruption of mesoderm and axis formation in fish by ectopic expression of activin variants: the role of maternal activin. Genes Dev 8:1448-1462
48. Meachem SJ, Ruwanpura SM, Ziolkowski J, Ague JM, Skinner MK, Loveland KL 2005 Developmentally distinct in vivo effects of FSH on proliferation and apoptosis during testis maturation. J Endocrinol 186:429-446
49. Nakamura T, Takio K, Eto Y, Shibai H, Titani K, Sugino H 1990 Activin-binding protein from rat ovary is follistatin. Science 247:836-838
50. Cipriano SC, Chen L, Kumar TR, Matzuk MM 2000 Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice. Endocrinology 141:2319-2327
51. Matzuk MM, Bradley A 1992 Cloning of the human activin receptor cDNA reveals high evolutionary conservation. Biochim Biophys Acta 1130:105-108
52. Wu TC, Jih MH, Wang L, Wan YJ 1994 Expression of activin receptor II and IIB mRNA isoforms in mouse reproductive organs and oocytes. Mol Reprod Dev 38:9-15
53. Kumar TR, Wang Y, Matzuk MM 1996 Gonadotropins are essential modifier factors for gonadal tumor development in inhibin-deficient mice. Endocrinology 137:4210-4216
54. Matzuk MM, Finegold MJ, Mishina Y, Bradley A, Behringer RR 1995 Synergistic effects of inhibins and Mullerian-inhibiting substance on testicular tumorigenesis. Mol Endocrinol 9:1337-1345
55. Mishina Y, Rey R, Finegold MJ, Matzuk MM, Josso N, Cate RL, Behringer RR 1996 Genetic analysis of the Mullerian-inhibiting substance signal transduction pathway in mammalian sexual differentiation. Genes Dev 10:2577-2587
56. Shou W, Woodruff TK, Matzuk MM 1997 Role of androgens in testicular tumor development in inhibin-deficient mice. Endocrinology 138:5000-5005
57. Burns KH, Agno JE, Sicinski P, Matzuk MM 2003 Cyclin D2 and p27 are tissue-specific regulators of tumorigenesis in inhibin α knockout mice. Mol Endocrinol 17:2053-2069
58. Cipriano SC, Chen L, Burns KH, Koff A, Matzuk MM 2001 Inhibin and p27 interact to regulate gonadal tumorigenesis. Mol Endocrinol 15:985-996
59. Finkelstein JS, O'Dea LS, Whitcomb RW, Crowley Jr WF 1991 Sex steroid control of gonadotropin secretion in the human male. II. Effects of estradiol administration in normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab 73:621-628
60. Clotman F, Lemaigre FP 2006 Control of hepatic differentiation by activin/TGFβ signaling. Cell Cycle 5:168-171
61. Yasuda H, Mine T, Shibata H, Eto Y, Hasegawa Y, Takeuchi T, Asano S, Kojima I 1993 Activin A: an autocrine inhibitor of initiation of DNA synthesis in rat hepatocytes. J Clin Invest 92:1491-1496
62. Schwall RH, Robbins K, Jardieu P, Chang L, Lai C, Terrell TG 1993 Activin induces cell death in hepatocytes in vivo and in vitro. Hepatology 18:347-356
63. Knight PG, Muttukrishna S, Groome NP 1996 Development and application of a two-site enzyme immunoassay for the determination of 'total' activin-A concentrations in serum and follicular fluid. J Endocrinol 148:267-279
64. O'Connor AE, McFarlane JR, Hayward S, Yohkaichiya T, Groome NP, de Kretser DM 1999 Serum activin A and follistatin concentrations during human pregnancy: a cross-sectional and longitudinal study. Hum Reprod 14:827-832
65. Pangas SA, Li X, Robertson EJ, Matzuk MM 2006 Premature luteinization and cumulus cell defects in ovarian-specific Smad4 knockout mice. Mol Endocrinol 20:1406-1422
66. Livak KJ, Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Δ Δ C(T)) method. Methods 25:402-408
67. Li Q, Kumar R, Underwood K, O'Connor AE, Loveland KL, Seehra JS, Matzuk MM, Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein. Mol Hum Reprod, in press